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Summary
 Background The presence of estrogen receptor (ER) in breast cancer cell is a good prognostic 
factor. It is also a predictive factor used in hormonal therapy.
 Aim To evaluate the expression of oestrogen receptors a and b (ERa and ERb) in the 
neoplastic tissues of patients with invasive breast cancer and to determine whether 
ERb expression may be correlated with some clinical parameters and biological 
markers.
 Materials/Methods Parafﬁ n embedded tissues from 67 patients with breast cancer were used in this 
study. Monoclonal antibodies against a oestrogen receptors, progesterone recep-
tors (DakoCytomation) and polyclonal antibodies against b oestrogen receptors 
(CHEMICON) were used. The EnVision detection system was applied.
 Results Expression of ERa was demonstrated in 57% of all patients, while in patients over 
50 years it was higher – 71%. Expression of ERb was demonstrated in 48% of pa-
tients and this percentage was not dependent on the age of the patients. In tu-
mours expressing ERb, expression of p53 and Ki-67 was less common. In addi-
tion, these tumours were of a lower grade of malignancy.
 Conclusions Our results demonstrate a negative correlation between the expression of ERb 
and the expression of p53 and Ki-67. The expression of ERb may be a good prog-
nostic indicator.
 Key words estrogen receptor b • breast cancer • immunohistochemistry
 Full-text PDF: http:/www.rpor.pl/pdf.php?MAN=7841
 Word count: 1497
 Tables: 2
 Figures: 4
 References: 16
 Author’s address: Maria Litwiniuk, Oncology Department, Poznań University of Medical Sciences, Łąkowa 1/2 Str.,
61-878 Poznań, Poland, e-mail: litwiniuk@skrzynka.pl
Received: 2004.04.07
Accepted: 2005.07.15
Published: 2005.09.20
Original Paper
173
Rep Pract Oncol Radiother, 2005; 10(4): 173-177
BACKGROUND
The presence of oestrogen receptors (ER) in 
breast cancer cells is a good prognostic factor. 
It is also a predictive factor used in hormonal 
therapy [1].
In 1996, several laboratories independently dis-
covered a second oestrogen receptor in rats, mice 
and humans. This newly discovered protein was 
named oestrogen receptor b (ERb) because a pro-
tein previously found to be a receptor had been 
named oestrogen receptor a (ERa) [2,3]. Two 
separate genes on two different chromosomes 
code for oestrogen receptors a and b. The gene 
coding for oestrogen receptor b, in humans, is 
found on chromosome 14, while the gene cod-
ing for oestrogen receptor a is found on the long 
arm of chromosome 6.
The function of oestrogen receptor b has not 
been fully explained. There is conﬂ icting infor-
mation regarding the prognostic value of the 
presence of oestrogen receptor b in breast can-
cer [4].
Antibodies that allow the demonstration of oes-
trogen receptor b, by means of immunohisto-
chemical tests, have recently become commer-
cially available.
AIM
The purpose of the study was to assess the ex-
pression of oestrogen receptors a and b in the 
tumours of patients diagnosed with invasive breast 
cancer, and to attempt to correlate the presence 
of the b receptor with the expression of selected 
immunohistochemical markers.
MATERIALS AND METHODS
The material for the study was comprised of his-
tological materials gathered from 67 consecu-
tive patients, operated in the Oncology Clinic 
of Poznan University of Medical Sciences, in the 
year 2002. Immunohistochemistry and micro-
scopy were also carried out in the University of 
Medical Sciences, in the Department of Tumour 
Pathology. Slides were produced from parafﬁ n 
wax blocks containing tissues ﬁ xed in 10% neu-
tral buffered formalin and processed to paraf-
ﬁ n by conventional histological methods. The 
EnVisionÔ + HRP complex (DAKO) was used in 
immunohistochemical methods. Monoclonal an-
tibodies against a oestrogen receptors and pro-
gesterone receptors (DakoCytomation), and poly-
clonal antibodies against b oestrogen receptors 
(CHEMICON), were used to demonstrate the 
presence of receptors. Also used were monoclonal 
antibodies against p53 protein, polyclonal anti-
bodies against cathepsin D and monoclonal an-
tibodies against Ki-67 (all by DAKO).
Statistical dependencies were tested for using 
Fisher’s exact test and the Fisher-Freeman-Halton 
test. Findings were assumed to be signiﬁ cant at 
the level of p <0.05.
RESULTS
The clinico-histological characteristics of the stu-
died group are shown in Table 1.
The presence of oestrogen receptor a was detec-
ted in the tumours of 57% of patients. In patients 
aged over 50 years this ﬁ gure rose to 71%.
Oestrogen receptor b was detected in the ne-
oplastic tissues of 48% of patients and was in-
dependent of the age of the patient. In 75% of 
cases where oestrogen receptor b was detected, 
a receptors were also found. Patients express-
ing oestrogen receptor b but lacking oestrogen 
receptor a accounted for only 12% of the stu-
died group. Positive immunohistochemical re-
sults for the presence of progesterone receptors 
were obtained from the tumours of 67% of pa-
tients. Relationships between receptor content 
values are presented in Table 2 and in Figure 1.
In the neoplastic tissues of patients expressing 
oestrogen receptor b, p53 protein was found less 
frequently than in the group studied as a whole 
(Figure 2). Furthermore, expression of cathep-
sin D and Ki-67 were also less frequently detect-
ed in this sub-group (Figure 3).
Among such patients neoplasms were frequent-
ly of a lower grade of malignancy, histologically 
(Figure 4). This difference was found to be sta-
tistically signiﬁ cant (p=0.001). Similarly, in the 
case of p53 protein and Ki-67 antigen, statistical-
ly signiﬁ cant differences were observed (p=0.004 
and p=0.02 respectively). However, in the case of 
cathepsin D, no statistically signiﬁ cant differ en-
ces were found (p=0.22).
DISCUSSION
The ﬁ rst investigations into b receptors were 
performed using mRNA, with the help of the 
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polymerase chain reaction (PCR). Such tests 
were necessary because of the lack of commer-
cially available antibodies for the detection of b 
receptor expression by immunological means. 
Our study was carried out using the immunohis-
Parameter Number of patients %
Age
   <40 years 4 6
   40–50 years 23 34
   >50 years 40 60
Size of tumour
   <2 cm 42 63
   >2 cm 25 37
Lymph nodes
   Uninvolved 25 37
   Involved 39 58
   Undetermined 3 5
Histological grade of malignancy
   G1 16 24
   G2 30 45
   G3 16 24
   Gx 5 7
Receptors
   ERα + 38 57
   ERβ + 32 48
   PgR + 45 67
Positive reaction – p53 21 31
Positive reaction – Ki-67 47 70
Positive reaction – cathepsin D 40 60
Table 1. Patient and tumour characteristics in the studied group.
Receptors ERβ+ ERβ–
ERα+ 36 21
ERα– 12 31
PgR+ 36 31
PgR– 12 21
ERα + PgR+ 33 19
ERα + PgR- 3 2
ERα – PgR+ 3 12
ERα – PgR– 9 19
Table 2. A comparison of ERα, ERβ and PgR protein expression in 
the tumours of the 67 patients studied (%).
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Figure 1. The relationship between ERβ and ERα expression in 67 
carcinomas (p=0.008).
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Figure 2. The relationship between over expression of p53 protein 
and expression of ERβ (p=0.004).
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Figure 3. Relationship between Ki-67 immunoreactivity and 
expression of ERβ (p=0.02).
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tochemistry method, which allowed us to assess 
archived materials, which is cheaper and more 
readily available. Many mono and polyclonal anti-
bodies for the detection of b receptor expression 
have recently been developed. The antibodies 
are directed against various fragments of oestro-
gen receptor b. The value of the immunohisto-
chemical method is the possibility to localize the 
sought antigen within cells without the danger 
of confusing it with non-malignant portions of 
the tumour. This could be of signiﬁ cance in the 
case of oestrogen receptor b as these receptors 
are often found, not only in normal glandular 
tissue, but also in blood vessels, as well as in adi-
pose tissue and connective tissues [5].
The results of this study showed that oestrogen re-
ceptor a could be demonstrated in the tumours of 
57% of patients and that this ﬁ gure rose to 71% 
in patients older than 50 years. These ﬁ ndings are 
in agreement with those of other authors [6].
Oestrogen receptor b was detected in 48% of pa-
tients, irrespective of age. This lack of an age relat-
ed link with expression of ERb is also in agreement 
with the results of other studies [7]. In 75% of these 
patients, both ERa and ERb were detected. Patients 
lacking oestrogen receptor a, but showing expres-
sion of oestrogen receptor b, account for 12% of 
the studied group. It is known that, in around 10% 
of patients with advanced breast cancer, it is possible 
to obtain a response to hormonal treatment and it 
is in these patients that no expression of ER a may 
be observed. Possibly this is the group of patients 
who are ERa negative and ERb positive.
The expression of p53 protein was detected in 
31% of tumours. The p53 gene produces p53 pro-
tein, which plays roles in the regulation of tran-
scription, the cell cycle and apoptosis. Mutations 
of this gene are found in many tumours, includ-
ing breast cancer. Immunohistochemistry has 
allowed the detection of excess p53 protein in 
22–25% of breast cancer cases. While the pres-
ence of mutations in gene p53 is not included 
among prognostic factors of deﬁ nite value, most 
research shows a negative relationship with im-
proper expression of p53 [8]. In our study, we 
found a negative correlation between the pres-
ence of ERb and p53. Nuclear accumulations of 
p53 protein were observed less frequently in pa-
tients expressing oestrogen receptor b than in 
the group as a whole.
Also tested was the dependence between the 
expression of ERb and the proliferative anti-
gen Ki-67. Over-expression of Ki-67 is associated 
with a poorer prognosis. We have found a nega-
tive correlation between the expression of Ki-67 
and ERb. Roger et al. also described this same 
dependency [9].
In order to better understand the purpose of b 
receptors in both normal and neoplastic tissues, 
mice were raised in which the gene coding for 
the receptors was inactive. In the breasts of these 
mice, improper growth of epithelia, multiple cysts 
and over-expression of Ki-67 were noted [10].
Current studies into the role of oestrogen recep-
tor b have provided conﬂ icting results. Speirs et 
al. used the RT-PCR method to assess the value of 
mRNA to ER a and ER b. They found that expres-
sion of oestrogen receptor b is associated with me-
tastases to the lymph nodes [11]. A similar study 
found no relationships between the mRNA lev-
els for ER a and b and the histological grade of 
malignancy, size of the tumour or involvement 
of the lymph nodes. The highest levels of mRNA 
for ERb are found in tumours which are ER and 
PR negative, and therefore, in tumours which are 
insensitive to hormonal treatment [12]. Because 
this relationship has also been shown in other stu-
dies it has been postulated that oestrogen recep-
tor b may be involved in resistance to tamoxifen 
therapy [13,14]. Mann et al. settled on opposing 
conclusions. Using immunohistochemistry, they 
assessed a and b oestrogen receptor status in a 
group of 118 women who took tamoxifen after 
surgery. Better survival times were recorded for 
women whose tumours had been found positive 
for b receptors in more than 10% of cells. This 
applied equally to patients with and without meta-
stases to the lymph nodes [15]. In another study, 
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Figure 4. Relationship between expression of ERβ and the 
histological grade of tumours (p=0.001).
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in which immunohistochemistry was used, a con-
nection was studied between ERb, ERa, PgR and 
selected prognostic factors. The presence of oes-
trogen receptor b correlated with a lack of metas-
tases to the lymph nodes, a low histological grade 
of malignancy, and a low fraction of cells in the 
synthesis phase. Over-expression of the HER-2 
receptor is seen signiﬁ cantly more frequently in 
patients whose tumours test positive for the pres-
ence of oestrogen receptor b [16].
CONCLUSIONS
In this study, we have found a negative corre-
lation between the expression of oestrogen re-
ceptor b and the expression of p53 protein and 
Ki-67 antigen.
The presence of oestrogen receptor b may turn 
out to be a useful prognostic factor.
However, further studies are needed to assess 
the prognostic value of testing for the presence 
of oestrogen receptor b in patients with breast 
cancer.
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